Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

Company Overview

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S. Food and Drug Administration for the treatment of pediatric growth hormone deficiency. By transiently conjugating active hormone to a carrier molecule, the TransCon platform allows controlled release of the therapeutic agent over time, reducing injection frequency and helping to maintain more consistent drug exposure.

Beyond growth hormone deficiency, Ascendis Pharma is advancing a pipeline of product candidates aimed at other rare endocrine disorders. TransCon parathyroid hormone (PTH) is in clinical development for hypoparathyroidism and has demonstrated positive proof‐of‐concept data. The company is also investigating TransCon CNP for the treatment of achondroplasia, a form of dwarfism, and pursuing additional indications in both endocrine and broader metabolic diseases.

Ascendis Pharma’s management team brings together experienced professionals in drug development, regulatory affairs and commercial strategy. The company continues to expand its global footprint through strategic collaborations and partnerships, with the goal of delivering transformative therapies to patients with underserved conditions.

Key Stats

• Today's Range: $259.20 to $267.50
• 50-Day Range: $205.81 to $277.18
• 52-Week Range: $160.86 to $282.15
• Volume: 349,902 shs
• Average Volume: 713,121 shs
• Market Capitalization: $16.43 billion
• P/E Ratio: 30.43
• Dividend Yield: N/A
• Price Target: $295.67
• Consensus Rating: Buy

Ascendis Pharma A/S Stock Analysis - MarketRank™

Ascendis Pharma A/S scored higher than 85% of companies evaluated by MarketBeat, and ranked 61st out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Buy

Consensus Rating

Ascendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.05, and is based on 2 strong buy ratings, 16 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Ascendis Pharma A/S has a consensus price target of $295.67, representing about 10.9% upside from its current price of $266.61.

Amount of Analyst Coverage

Ascendis Pharma A/S has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 162.20%

Earnings Growth

Earnings for Ascendis Pharma A/S are expected to grow by 162.20% in the coming year, from $4.63 to $12.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ascendis Pharma A/S is 30.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.08.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ascendis Pharma A/S is 30.76, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.22.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.76% of the float of Ascendis Pharma A/S has been sold short.

Short Interest Ratio / Days to Cover

Ascendis Pharma A/S has a short interest ratio ("days to cover") of 2.52, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ascendis Pharma A/S has recently increased by 64.96%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ascendis Pharma A/S does not currently pay a dividend.

Dividend Growth

Ascendis Pharma A/S does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.87

News Sentiment

Ascendis Pharma A/S has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Ascendis Pharma A/S this week, compared to 5 articles on an average week.

Search Interest

14 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.

MarketBeat Follows

4 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Selling Shares

Cluster Insider Buying

2 insiders have purchased shares of Ascendis Pharma A/S in the last three months. Multiple insiders buying is a strong bullish signal.

Insider Buying vs. Insider Selling

In the past three months, Ascendis Pharma A/S insiders have sold 3,866.00% more of their company's stock than they have bought. Specifically, they have bought $117,020.00 in company stock and sold $4,641,015.00 in company stock.

Percentage Held by Insiders

40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Ascendis Pharma A/S has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 7/17/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASND
• CIK: 1612042
• Web: www.ascendispharma.com
• Phone: (457) 022-2244
• Fax: 45-3694-4010
• Employees: 1,189
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Ascendis Pharma A/S: $295.67
• High Price Target: $355.00
• Low Price Target: $255.00
• Potential Upside/Downside: +11.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.05
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.67
• Trailing P/E Ratio: 30.52
• Forward P/E Ratio: 57.18
• P/E Growth: N/A
• Net Income: -$258 million
• Net Margins: 57.87%
• Pretax Margin: -19.73%
• Return on Equity: N/A
• Return on Assets: -8.37%

Debt

• Debt-to-Equity Ratio: 0.79
• Current Ratio: 1.00
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $814.57 million
• Price / Sales: 20.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.97) per share
• Price / Book: -89.14

Miscellaneous

• Outstanding Shares: 62,380,000
• Free Float: 37,426,000
• Market Cap: $16.51 billion
• Optionable: Optionable
• Beta: 0.37